Janux Therapeutics (NASDAQ:JANX) Issues Quarterly Earnings Results

Janux Therapeutics (NASDAQ:JANX) issued its quarterly earnings data on Wednesday. The company reported ($0.51) EPS for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.18), Briefing.com reports. The company had revenue of $0.44 million for the quarter, compared to analyst estimates of $1.50 million. Janux Therapeutics had a negative return on equity of 8.78% and a negative net margin of 291.17%. The business’s revenue was down 82.6% compared to the same quarter last year.

Janux Therapeutics Trading Down 1.2 %

JANX stock traded down $0.68 on Thursday, hitting $54.21. 705,575 shares of the company’s stock traded hands, compared to its average volume of 713,085. The stock has a market cap of $2.83 billion, a price-to-earnings ratio of -59.36 and a beta of 3.52. Janux Therapeutics has a 1-year low of $5.65 and a 1-year high of $65.60. The stock has a fifty day moving average of $48.69 and a 200-day moving average of $46.30.

Insider Buying and Selling at Janux Therapeutics

In related news, CEO David Alan Campbell sold 25,000 shares of Janux Therapeutics stock in a transaction on Monday, October 28th. The stock was sold at an average price of $53.54, for a total value of $1,338,500.00. Following the transaction, the chief executive officer now directly owns 282,054 shares in the company, valued at $15,101,171.16. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. In other news, CEO David Alan Campbell sold 25,000 shares of Janux Therapeutics stock in a transaction that occurred on Monday, October 28th. The shares were sold at an average price of $53.54, for a total value of $1,338,500.00. Following the transaction, the chief executive officer now directly owns 282,054 shares of the company’s stock, valued at $15,101,171.16. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Andrew Hollman Meyer sold 50,000 shares of the company’s stock in a transaction that occurred on Friday, September 27th. The shares were sold at an average price of $45.96, for a total transaction of $2,298,000.00. Following the completion of the sale, the insider now owns 67,592 shares of the company’s stock, valued at approximately $3,106,528.32. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 420,610 shares of company stock valued at $19,288,666. Corporate insiders own 29.40% of the company’s stock.

Analysts Set New Price Targets

JANX has been the subject of a number of recent analyst reports. Stifel Nicolaus initiated coverage on shares of Janux Therapeutics in a report on Friday, September 6th. They set a “buy” rating and a $70.00 price target for the company. Scotiabank cut their target price on Janux Therapeutics from $47.00 to $42.00 and set a “sector perform” rating on the stock in a research report on Friday, August 9th. Cantor Fitzgerald reiterated an “overweight” rating and set a $100.00 price objective on shares of Janux Therapeutics in a research note on Thursday. HC Wainwright reaffirmed a “buy” rating and set a $63.00 price target on shares of Janux Therapeutics in a research report on Thursday. Finally, UBS Group started coverage on Janux Therapeutics in a research report on Thursday, October 24th. They issued a “buy” rating and a $69.00 target price for the company. One research analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $66.44.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.